ADVERTISEMENT
Poster
1587538
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Including in a Subgroup With Energy/Concentration Symptoms: Time to Efficacy Onset
Psych Congress 2023
This work was sponsored by Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and Lundbeck LLC (Deerfield, IL, USA).
Many patients with major depressive disorder (MDD) experience unresolved depressive symptoms following antidepressant treatment (ADT), including energy and concentration issues. This post hoc analysis explored time to onset of efficacy of adjunctive brexpiprazole in patients with MDD, including in a subgroup of patients with baseline energy and concentration symptoms.
Data were pooled from three fixed-dose studies of adjunctive brexpiprazole in adults with MDD. Patients with inadequate response to ADT were randomized to ADT + placebo or ADT + brexpiprazole. The primary endpoint in each study was the change from baseline to Week 6 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total score. Presence of baseline energy and concentration symptoms was defined as a score ≥1 on Inventory of Depressive Symptomatology – Self-Report items 15 (Concentration/decision making), 20 (Energy level), 23 (Feeling slowed down) and 30 (Leaden paralysis/physical energy).
In the total sample, on the change in MADRS Total score, separation (p
Sign Up
Psych Congress Network Newsletter
